Evidence map›Paper›PMID 32498585›Full record

ArticleImmunological investigations2020

Microspheres Encapsulating Immunotherapy Agents Target the Tumor-Draining Lymph Node in Pancreatic Ductal Adenocarcinoma.

Booyeon J Han, Joseph D Murphy, Shuyang Qin, Jian Ye, Taylor P Uccello, Jesse Garrett-Larsen, Brian A Belt, Peter A Prieto, Nejat K Egilmez, Edith M Lord and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunological investigations, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Synthesis, Characterization, andJournal of immunology research · 2022
    Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Booyeon J HanDepartment of Microbiology and Immunology, University of Rochester Medical Center , Rochester, NY, USA.
Joseph D MurphyDepartment of Microbiology and Immunology, University of Rochester Medical Center , Rochester, NY, USA.
Shuyang QinDepartment of Microbiology and Immunology, University of Rochester Medical Center , Rochester, NY, USA.
Jian YeDepartment of Surgery, University of Rochester Medical Center , Rochester, NY, USA.
Taylor P UccelloDepartment of Microbiology and Immunology, University of Rochester Medical Center , Rochester, NY, USA.
Jesse Garrett-LarsenDepartment of Surgery, University of Rochester Medical Center , Rochester, NY, USA.
Brian A BeltDepartment of Surgery, University of Rochester Medical Center , Rochester, NY, USA.
Peter A PrietoDepartment of Surgery, University of Rochester Medical Center , Rochester, NY, USA.
Nejat K EgilmezDepartment of Microbiology and Immunology, University of Louisville School of Medicine , Louisville, KY, USA.
Edith M LordDepartment of Microbiology and Immunology, University of Rochester Medical Center , Rochester, NY, USA.
David C LinehanDepartment of Surgery, University of Rochester Medical Center , Rochester, NY, USA.
Bradley N MillsDepartment of Surgery, University of Rochester Medical Center , Rochester, NY, USA.
Scott A GerberDepartment of Microbiology and Immunology, University of Rochester Medical Center , Rochester, NY, USA.
University of Rochester Medical Center · USUniversity of Louisville · US

Funding

The T32 Predoctoral Training Program in Immunology (PTPI)T32AI007285 · NIAID · UNIVERSITY OF ROCHESTER · PI Scott Andrew Gerber, JACQUES Robert · 1986 to 2026
$7.6M
Training Program in Oral ScienceT90DE021985 · NIDCR · UNIVERSITY OF ROCHESTER · PI OVITT, CATHERINE, YULE, DAVID I · 2011 to 2021
$5.6M
IN SITU ANTITUMOR IMMUNITY AND EFFECTS OF RADIATIONR01CA028332 · NCI · UNIVERSITY OF ROCHESTER · PI LORD, EDITH M · 1985 to 2020
$5.0M
Modulating innate immune cells in the tumor microenvironment of pancreas cancer to enhance anti-tumor immunityR01CA168863 · NCI · WASHINGTON UNIVERSITY · PI LINEHAN, DAVID C · 2013 to 2023
$3.6M
Development of a New Strategy to Treat Locally Advanced Pancreatic CancerR01CA230277 · NCI · UNIVERSITY OF ROCHESTER · PI GERBER, SCOTT ANDREW · 2019 to 2023
$2.0M
SARRP 200 Platform for Image Guided Micro IrradiationS10OD021548 · OD · UNIVERSITY OF ROCHESTER · PI WILLIAMS, JACQUELINE PATRICIA · 2016 to 2016
$600k
NCI NIH HHS R01 CA028332NCI NIH HHS R01 CA168863NCI NIH HHS R01 CA230277NIAID NIH HHS T32 AI007285NIDCR NIH HHS T90 DE021985NIH HHS S10 OD021548
6 · The paper itself

Abstract

introductionThe tumor-draining lymph node (TDLN) plays a role in tumor immunity. Intratumorally administered microspheres (MS) that encapsulate immunomodulatory agents have emerged as a treatment strategy capable of causing profound changes in the tumor microenvironment (TME) and eliciting potent antitumor effects. We hypothesized that local delivery of MS to the TME may also drain to and therefore target the TDLN to initiate antitumor immune responses.

methodsFluorescent MS were injected into orthotopically implanted murine pancreatic tumors, and tissues were examined by whole-mount microscopy and imaging flow cytometry. The role of the TDLN was investigated for mice treated with intratumoral interleukin-12 (IL-12)-encapsulated MS in combination with stereotactic body radiotherapy (SBRT) by cytokine profile and TDLN ablation.

resultsFluorescent AF-594 MS delivered intratumorally were detected in the tumor, peritumoral lymphatics, and the TDLN 2 h after injection. Phagocytic cells were observed with internalized fluorescent MS. SBRT + IL-12 MS-induced upregulation of Th1 and antitumor factors IL-12, IFN-γ, CXCL10, and granzyme B in the TDLN, and excision of the TDLN partially abrogated treatment efficacy.

conclusionsOur results demonstrate that intratumorally administered MS not only target the TME, but also drain to the TDLN. Furthermore, MS encapsulated with a potent antitumor cytokine, IL-12, induce an antitumor cytokine profile in the TDLN, which is essential for treatment efficacy.

Indexed as

MicrospheresAnimalsAntineoplastic Agents, ImmunologicalBiomarkersBiomarkers, TumorCarcinoma, Pancreatic DuctalCombined Modality TherapyDisease ManagementDisease Models, AnimalFemaleHumansImmunophenotypingLymph NodesMiceMolecular Targeted TherapyPancreatic NeoplasmsAntineoplastic Agents, ImmunologicalBiomarkersBiomarkers, Tumorimmunotherapyinterleukin-12 (IL-12)microparticlepancreatic ductal adenocarcinoma (PDA)Tumor-draining lymph node (TDLN)

Identifiers

PMID32498585
PMCPMC7904097
OpenAlexW3033025181

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.